Seeking Alpha

Celgene (CELG +0.9%) finishes the day in the positive after U.S. regulators approved its...

Celgene (CELG +0.9%) finishes the day in the positive after U.S. regulators approved its Abraxana medication, a first-line treatment of advanced non-small cell lung cancer in patients not being treated surgically or with radiation therapy.
From other sites
Comments (1)
  • HarryKlari
    , contributor
    Comments (6) | Send Message
     
    This is a Billion dollar drug...then comes pancreatic cancer and melanoma and other indications. Looks like today's bright lights bought on the rumor and sold on the news. made pennies. lost opportunities for real wealth. Celg is a screaming bargain IMHO
    12 Oct 2012, 07:11 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs